The drug is the first and only approved oral, controlled-release budesonide treatment for UC patients when mesalazine treatment is not sufficient.
The company also released new data from the CONTRIBUTE trial that showed that adding CORTIMENTMMX 9 mg was significantly more effective than placebo at inducing combined clinical and endoscopic remission in UC patients experiencing a flare up despite oral mesalazine therapy.
More articles on GI/endoscopy:
7 things for gastroenterologists to know for today
GI/endoscopy company stock report – Feb. 20, 2015
What gastroenterologists can expect from a physician shortage
